Ask the Doctor Archives at Bladder Cancer Advocacy Network – BCAN


Newsletter Ask the Doctor Archives Subscribe to Newsletter Quick Links Frequently Asked Questions BCG Shortage Information Join Our Mailing List Clinical Trials Clinical Trials Matching Service Volunteer Donate Patient Tips Online Store Walk for Bladder Cancer What's Up, Doc? The Bladder Cancer Advocacy Network (BCAN) is proud to announce that we have been designated a Marine Corps Marathon (MCM) Charity Partner! BCAN has been allocated 25 guaranteed entries for the 38th Annual Marine Corps Marathon to be held on October 27, 2013; an event that sold out in 2 hours and 41 minutes in 2012. We are looking at building “Team BCAN” to not only run in the event and raise awareness for bladder cancer but to raise needed funds for fostering research and patient education. According to the Marine Corps Marathon, there is not a required qualifying time to participate in the event, but all runners should maintain at least a 14 minute mile pace. In order to become a member of “Team BCAN” and officially have a slot in this year’s race, you must be registered through BCAN. No federal or Marine Corps endorsement is implied. If you are interested in becoming a member of BCAN’s team or have any questions, please contact Larry Rzepka, BCAN’s Executive Director, at lrzepka@bcan.org.	Ask the Doctor Archives *Diagnosis* A1BG as Possible Biomarker for Bladder Cancer Summer 2007 Dr. Cheryl Lee, M.D. Assistant Professor of Urology, University of Michigan Common Terminology in Urine Cytology and Biopsy Reports Fall 2008 Dr. Donna Hansel, M.D. Assistant Professor, Department of Pathology and Laboratory Medicine at Taussig Cancer Center at Cleveland Clinic Diagnostic Markers for Bladder Cancer Spring 2008 Dr. Badrinath Konety, M.D. Associate Professor, Departments of Urology, Epidemiology and Biostatistics, University of California, San Francisco FISH Test Winter 2007 Dr. Michael O’Donnell, M.D. Holden Cancer Center, University of Iowa Hospital Metastatic Bladder Cancer Summer 2006 Dr. Walter Stadler, M.D. Professor and Director of Genitourinary Oncology at the University of Chicago NMP22 Screening Test Fall 2006 Dr. Mark Soloway, M.D. Professor and Chair, Department of Urology, Miller School of Medicine, University of Miami Superficial Bladder Cancer Terminology Fall 2006 Dr. Mark Soloway, M.D. Professor and Chair, Department of Urology, Miller School of Medicine, University of Miami *Treatment:* After Surgery Spring/Summer 2009 Dr. Matthew Nielsen, M.D. University of North Carolina at Chapel Hill Dr. Nielsen discusses bladder removal surgery (radical cystectomy) and the potential short-term as well as long-term issues that may arise from this major operation. Age-Specific Therapies Spring 2008 Dr. Badrinath Konety, M.D. Associate Professor, Departments of Urology, Epidemiology and Biostatistics, University of California, San Francisco Bladder Tissue Engineering Spring 2006 Dr. Seth Lerner, M.D. Associate Professor of Urology, Beth and David Swaim Chair in Urological Oncology and Scott Department of Urology, Baylor College of Medicine Urinary Diversion Updates Summer 2008 Dr. Michael Cookson, M.D. Professor of Urologic Surgery at Vanderbilt University in Nashville, Tennessee Urinary Tract Infection Prevention Fall 2007 Dr. Donald Lamm, M.D. President of BCG Oncology Use of Antioxidants Spring 2007 Dr. Ashish Kamat, M.D. Assistant Professor, Urology & Cancer Biology at the University of Texas-MD Anderson Cancer Center BCG BCG Maintenance – Pros and Cons Spring 2006 Dr. Mark Schoenberg, M.D. Professor of Urology and Oncology and Director of Urologic Oncology at the James Buchanan Brady Urological Institute of Johns Hopkins Medical Institutions Safety of Sexual Intercourse Winter 2008 Dr. Arthur Sagalowsky, M.D. Professor and Chief of Urologic Oncology at UT Southwestern Medical Center Side Effects Spring 2006 Dr. Seth Lerner, M.D. Associate Professor of Urology, Beth and David Swaim Chair in Urological Oncology and Scott Department of Urology, Baylor College of Medicine Updates on BCG Treatment Fall 2007 Dr. Donald Lamm, M.D. President of BCG Oncology What if you don’t respond to BCG Winter 2007 Dr. Michael O’Donnell, M.D. Holden Cancer Center, University of Iowa Hospital Chemotherapy Difference between neo-adjudvant and adjudvant chemotheraphy Summer 2006 Dr. Walter Stadler, M.D. Professor and Director of Genitourinary Oncology at the University of Chicago Systemic Chemotherapy Fall 2009 Dr. Deborah Bradley, M.D. Assistant Professor of Medicine, Duke University Medical Center Dr. Bradley discusses when systemic chemotherapy is appropriate, and whether it should be offered before or after radical cystectomy. Cystectomy Advantages/Disadvantages of Robotic Cystectomy Procedure Winter 2010 Dr. Mark Gonzalgo, M.D. Associate Professor of Urology and Director of Robotic-Assisted Urologic Cancer Surgery at Stanford University Dr. Gonzalgo shares his expertise on the advantages and disadvantages of robotic cystectomy compared to open cystectomy. Radical Cystectomy Summer 2008 Dr. Michael Cookson, M.D. Professor of Urologic Surgery at Vanderbilt University in Nashville, Tennessee Recommended Follow-up Winter 2008 Dr. Arthur Sagalowsky, M.D. Professor and Chief of Urologic Oncology at UT Southwestern Medical Center Urinary Diversions Ileal Conduit November 2010 Questions and Answers with Nancy, a bladder cancer survivor with an ileal conduit The Continent Cutaneous Pouch (CCP) or Indiana Pouch November 2010 Questions and Answers with Karen, a bladder cancer survivor living with CCP Neobladder November 2010 Questions and answers with Michael, a bladder cancer survivor living with a neobladder *Recurrence* Development of More Aggressive High Grade Tumors Summer 2007 Dr. Cheryl Lee, M.D. Assistant Professor of Urology, University of Michigan Is it the case that the longer a person goes without recurrence, the greater the chance recurrence will never occur? Fall 2006 Dr. Mark Soloway, M.D. Professor and Chair, Department of Urology, Miller School of Medicine, University of Miami Why does Bladder Cancer have such a high recurrence rate? Winter 2007 Dr. Michael O’Donnell, M.D. Holden Cancer Center, University of Iowa Hospital *Survivorship* Can bladder cancer survivors ever call themselves cued? Spring 2006 Dr. Seth Lerner, M.D. Associate Professor of Urology, Beth and David Swaim Chair in Urological Oncology and Scott Department of Urology, Baylor College of Medicine Cancer survivorship issues Winter 2009 Dr. David Latini, Ph.D Assistant Professor of Urology at Baylor College of Medicine Dr. Latini discusses what bladder cancer survivors can do to improve quality of life for themselves and their families. Diet Spring 2007 Dr. Ashish Kamat, M.D. Assistant Professor, Urology & Cancer Biology at the University of Texas-MD Anderson Cancer Center	Search Our Site

Home | Financials | Privacy Policy | Site Map | Contact Us

4915 St. Elmo Avenue, Suite 202, Bethesda, Maryland 20814
PHONE: (301) 215-9099 TOLLFREE: 888-901-BCAN EMAIL: info@bcan.org

Find BCAN on Facebook

Follow BCAN on Twitter

Hope After Recurrence